Caris Life Sciences CAI

Caris Life Sciences FY 2025: revenue $812.0M; diluted EPS −$3.22

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Caris Life Sciences reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$812.0MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$68.1MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$3.22No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$796.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations$83.2MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

Get an email when Caris Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

Data on this page was fetched . The filing on SEC.gov is the record.